ddblog.labcorp.comInsights From Our Labs to Yours - Labcorp Blog

Insights From Our Labs to Yours Labcorp Blog Navigation Home Industry Device Drug Chemical Crop Phase Discovery Preclinical/Nonclinical Phase I-IIa Phase IIb-III Pilot Pivotal Formulation, Packaging, etc. Molecule Type Biologics Small Molecules Biosimilars Biomarkers Cell/Gene Therapies Data/Informatics SEND Modeling Patient Recruitment XcellerateCareers and Culture Contact Us Labcorp Drug Development Search for: UK-REACH Planning Top considerations for developing a biomarker solution and CDx strategy How to de-risk OECD 443 studies through optimized dose level selections Share What does a central lab do? 4 core services to know by Labcorp updated on Monday, April 24, 2023 Monday, April 24, 2023 Every clinical trial relies on data from its study participants to inform decisions regarding the safety and efficacy of a potential new treatment. Clinical trial sponsors rely on the data from laboratory tests to bring clear insights that advance studies. Labcorp Central Laboratory Services generates more clinical trial data than … Share Faster access to biopesticide alternatives to conventional pesticides under the U.S. BPPD regulatory framework by Labcorp updated on Thursday, April 20, 2023 Thursday, April 20, 2023 There is pressure worldwide for better, faster access to biological alternatives to conventional crop protection chemicals (CPCs). The U.S. Environmental Protection Agency (EPA) is ahead of regions such as the European Union (EU) in revising its regulatory approaches for biopesticides and in having a division dedicated to them, namely, the … Share Alcohol-related liver disease: Inherent Challenges and Strategies for Successful Clinical Trial Conduct by Kate Richardson, Director, CVMER, Operational Strategy and Planning and Peter Alfinito, PhD, Executive Director, CVMER, Operational Strategy and Planning updated on Wednesday, April 19, 2023 Monday, April 17, 2023 The association between excessive alcohol consumption and liver disease is well documented. In fact, the effect on alcohol consumption levels during the COVID-19 pandemic has more recently been investigated. In a 2022 Hepatology article, researchers estimated that the one-year increase in alcohol consumption during the pandemic would result in an … Share Program management services are now offered as part of Labcorp’s Preclinical Oncology Services by Labcorp updated on Wednesday, March 8, 2023 Wednesday, March 8, 2023 When it comes to discoveries in oncology, cancer patients can’t wait, which means neither can you. At Labcorp Preclinical Oncology, we understand there are many steps, phases and regulations to wade through to get to a lead drug candidate—all while time is of the utmost importance. We are excited to … Share Enabling better access to kidney disease trials by Peter Alfinito, Executive Director, CVMER, Operational Strategy and Planning; JB Flinders, Senior Director, CVMER, Operational Strategy and Planning updated on Tuesday, March 7, 2023 Tuesday, March 7, 2023 March is National Kidney Month, and we at Labcorp are committed to improving the renal health of patients worldwide. The field of nephrology clinical research has been steadily adding new interventional trials over the last five years at an average pace of 176 trials per year. This activity reflects the … Share Innovative collaboration between Biomakers and Labcorp to provide greater access to oncology patients in Latin America by Labcorp updated on Friday, February 17, 2023 Friday, February 17, 2023 In December 2022, Labcorp and Biomakers signed an agreement that will positively impact thousands of cancer patients in Latin America through greater access to diagnostic molecular profiling and participation in clinical trials. We recently asked Nicolas Kirchuk (NK), CEO and co-founder of Biomakers, and Isagani Chico (IC), MD, VP, global … Share Delivering solutions to the next generation of cardiovascular medicines by JB Flinders, Senior Director, CVMER, Operational Strategy and Planning and Peter Alfinito, Executive Director, CVMER, Operational Strategy and Planning updated on Monday, February 6, 2023 Monday, February 6, 2023 JB Flinders, Senior Director, CVMER, Operational Strategy and Planning and Peter Alfinito, Executive Director, CVMER, Operational Strategy and Planning February is American Heart Month, and we at Labcorp are dedicated to improve the cardiovascular health of patients worldwide, as part of Labcorp’s mission to improve health and improve lives. This … Share Improving access to rare disease trials by incorporating DCT elements by Dr. Marc Goldstein, Marketing Strategy Director, Decentralized Clinical Trials updated on Friday, February 3, 2023 Friday, February 3, 2023 Welcome to the February 2023 Labcorp Drug Development Decentralized Clinical Trial (DCT) blog. With Rare Disease Day coming soon on February 28, we are going to focus on how patients, sites and investigators can benefit by improving the design and execution of rare disease trials. What is Rare Disease Day? … Share 4 emerging trends to watch in immunotherapy clinical trials by Labcorp updated on Monday, April 17, 2023 Tuesday, January 17, 2023 Approaches to systemic anticancer therapy have shifted in recent decades. The nonspecific cytotoxic agents that once dominated the oncotherapy space first gave way to more targeted agents in the 1980s and 1990s, after which advanced, novel immunotherapeutic strategies took center stage. The potential of such immunotherapies to address untreatable malignancies … Share What the latest changes to EU regulations and data requirements mean for your microbial biopesticide registrations and renewals by Labcorp updated on Monday, January 9, 2023 Monday, January 9, 2023 Despite perceptions that biopesticides are inherently less dangerous, the EU regulates them as stringently as conventional, potentially highly hazardous, synthetic plant protection chemicals (Regulation [EC] No. 1107/2009). This has made approvals costly and slow. Recent regulatory revisions intended to redress this—to give EU farmers better and faster access to biological … Category(1) Analytical Services (3) Antibodies (1) Autoimmune/Inflammatory (7) Biologics (7) Biomarkers (6) Biosimilars (3) Cell/Gene Therapies (8) Chemical (19) Clinical Development (52) Clinical Testing (11) CNS (1) Commercialization (15) Consulting (2) Crop (19) Data/Informatics (10) Decentralized Clinical Trials (16) Device (8) Discovery (7) Drug (116) General Medicine (1) Health Economics & Market Access (4) Healthcare (1) Immunology (2) Industry (1) Infectious Disease (2) Inhalation (1) Lead Optimization (4) Manufacturing Support (1) Metabolic/Endocrine (2) Metabolism & PK (2) Molecule Type (1) NASH (1) Nephrology (1) Oncology (37) Pathology (1) Patient Recruitment (2) Phase I-IIa (39) Phase IIb-III (66) Pilot (4) Pivotal (10) Preclinical/Nonclinical (101) Pulmonary/Respiratory (5) Rare Disease (5) Regulatory Agencies (1) Regulatory Milestones (1) Reproductive Health (1) Risk Management (3) Routes (1) Safety (2) Safety Assessment (8) SEND (4) Small Molecules (3) Technology Services (2) Therapeutic Area (1) Uncategorized (6) Vaccine (2) Xcellerate (7) Archives Archives Select Month October 2023 July 2023 June 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 August 2022 July 2022 June 2022 May 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 July 2021 June 2021 May 2021 April 2021 March 2021 February 2021 January 2021 December 2020 November 2020 October 2020 September 2020 August 2020 July 2020 June 2020 May 2020 April 2020 March 2020 February 2020 January 2020 December 2019 October 2019 September 2019 May 2019 April 2019 February 2019 January 2019 December 2018 November 2018 October 2018 September 2018 August 2018 July 2018 June 2018 May 2018 March 2018 February 2018 January 2018 November 2017 October 2017 September 2017 August 2017 July 2017 June 2017 May...